Back to today’s briefing

Story perspectives

Revolutionary Menstrual Pad Aims to Boost Cervical Cancer Screenings

7/4/2025

26 3

Summary

Story summary

Cervical cancer screenings in the U.S. have plummeted, leaving one in four women overdue for vital tests. The discomfort of Pap smears plays a significant role in this decline. In response, CELLECT Laboratories is innovating a non-invasive menstrual pad that detects HPV and cervical cancer, striving to empower women, particularly trauma survivors, with a more approachable screening option.

1 of 1

Story summary

Cervical cancer screenings in the U.S. have plummeted, leaving one in four women overdue for vital tests. The discomfort of Pap smears plays a significant role in this decline. In response, CELLECT Laboratories is innovating a non-invasive menstrual pad that detects HPV and cervical cancer, striving to empower women, particularly trauma survivors, with a more approachable screening option.